Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Abbott Laboratories (NYSE:ABT) is preparing to release its quarterly earnings on Thursday, 2025-07-17. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

I think I have uncovered the real reason why Abbott Laboratories (NYSE:ABT) decided to spin off its pharmaceutical division into AbbVie Inc (NYSE:ABBV). The new company — now focused solely on medical ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock price ...

Discover why Abbott Laboratories (ABT) earns a buy rating with strong fundamentals, dividend growth, and growth prospects.

Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was extreme. Stream ...

ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat ...

Abbott Labs is a well-established medical device giant with a robust, diversified business. The healthcare giant has an incredible innovative streak that has allowed it to remain a leader. Abbott is ...

Get the live share price of Abbott Laboratories (ABT), including intraday charts, historical performance, key financials, and market updates. Track the latest US stock market activity.